Lee, CH
Wu, MZ
Lui, DTW
Fong, CHY
Ren, QW
Yu, SY
Yuen, MMA
Chow, WS
Huang, JY
Xu, A
Yiu, KH
Lam, KSL
Funding for this research was provided by:
Research Grants Council, University Grants Committee (Area of Excellence (AoE/M/707-18))
Article History
Received: 16 April 2022
Accepted: 23 September 2022
First Online: 5 November 2022
Declarations
:
: The study protocols were approved by the Institutional Review Board of the University of Hong Kong / Hospital Authority Hong Kong West Cluster (Ref: UW 07-378 and UW 11–121, respectively). Written informed consent was obtained from all recruited participants prior to any study related procedures.
: All authors have approved the manuscript and agreed with its publication.
: K.S.L. is an advisory board member of Merck Sharp and Dohme. C.H.L. received speaker’s fees from AstraZeneca, Bayer and Sanofi Aventis. The remaining authors have no conflict of interests.